Market Cap 125.96M
Revenue (ttm) 3.55M
Net Income (ttm) -14.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -419.15%
Debt to Equity Ratio 0.00
Volume 155,500
Avg Vol 208,150
Day's Range N/A - N/A
Shares Out 20.92M
Stochastic %K 15%
Beta 0.20
Analysts Strong Sell
Price Target $16.00

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
Dubs0121
Dubs0121 Dec. 6 at 3:41 PM
$COYA buyout incoming?
1 · Reply
Jwa68
Jwa68 Dec. 6 at 1:41 PM
$COYA Writing appears on the wall... https://insights.citeline.com/scrip/drug-combinations-may-be-the-next-generation-of-alzheimers-treatment-MK6OG44FR5BDHIJBJNZ3ELVODE/ Looks like big pharma likes the combination approach that Coya has been pursuing.
0 · Reply
Jwa68
Jwa68 Dec. 5 at 9:59 PM
$COYA For Fillit, the next important Alzheimer’s target to watch is inflammation. “My personal view is that inflammation is a very important target in this illness, both systemic and neuroinflammation,” ADDF has invested in some of these companies, including Houston-based Coya Therapeutics. Coya is studying COYA 302 in a Phase II trial for amyotrophic lateral sclerosis, but the regulatory T cell (Treg)-targeted therapy is also in early-stage development in frontotemporal dementia, Alzheimer’s and Parkinson’s disease. https://www.biospace.com/drug-development/eisai-still-confident-in-anti-tau-asset-as-j-j-becomes-latest-victim-in-spiraling-space
1 · Reply
QuantumTrade9
QuantumTrade9 Dec. 5 at 8:34 PM
$COYA biotech with thin liquidity, catalysts can reprice the whole range
1 · Reply
NickB01
NickB01 Dec. 5 at 8:25 PM
$COYA Added a few shares.
0 · Reply
Jwa68
Jwa68 Dec. 4 at 12:52 PM
$COYA World class team with goals alligned with shareholders. If I had free cash to deploy, it would be going here. Still expect Dr. Reddy’s acquires them in Q2 of 26 at 18 to 24. Do your dd. Deep value, strong asymmetric risk.
1 · Reply
Dubs0121
Dubs0121 Dec. 3 at 2:53 PM
$COYA we still like it here?
1 · Reply
Robby83
Robby83 Dec. 2 at 5:20 PM
$COYA added some more. Charts still looking very healthy
1 · Reply
irf944
irf944 Dec. 2 at 4:57 PM
$COYA Added. It's sitting right at support. Per Chartmill.....COYA does show a decent setup pattern. Prices have been consolidating lately. There is very little resistance above the current price. We notice that large players showed an interest for COYA in the last couple of days, which is a good sign.
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 30 at 5:40 AM
won't chase $COYA here. waiting for H% to cool like others shown
1 · Reply
Latest News on COYA
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 5:17 PM EST - 10 months ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD


Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 31, 2024, 10:31 AM EDT - 1 year ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off


Coya Therapeutics Announces $10.0 Million Private Placement

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Coya Therapeutics Announces $10.0 Million Private Placement


Dubs0121
Dubs0121 Dec. 6 at 3:41 PM
$COYA buyout incoming?
1 · Reply
Jwa68
Jwa68 Dec. 6 at 1:41 PM
$COYA Writing appears on the wall... https://insights.citeline.com/scrip/drug-combinations-may-be-the-next-generation-of-alzheimers-treatment-MK6OG44FR5BDHIJBJNZ3ELVODE/ Looks like big pharma likes the combination approach that Coya has been pursuing.
0 · Reply
Jwa68
Jwa68 Dec. 5 at 9:59 PM
$COYA For Fillit, the next important Alzheimer’s target to watch is inflammation. “My personal view is that inflammation is a very important target in this illness, both systemic and neuroinflammation,” ADDF has invested in some of these companies, including Houston-based Coya Therapeutics. Coya is studying COYA 302 in a Phase II trial for amyotrophic lateral sclerosis, but the regulatory T cell (Treg)-targeted therapy is also in early-stage development in frontotemporal dementia, Alzheimer’s and Parkinson’s disease. https://www.biospace.com/drug-development/eisai-still-confident-in-anti-tau-asset-as-j-j-becomes-latest-victim-in-spiraling-space
1 · Reply
QuantumTrade9
QuantumTrade9 Dec. 5 at 8:34 PM
$COYA biotech with thin liquidity, catalysts can reprice the whole range
1 · Reply
NickB01
NickB01 Dec. 5 at 8:25 PM
$COYA Added a few shares.
0 · Reply
Jwa68
Jwa68 Dec. 4 at 12:52 PM
$COYA World class team with goals alligned with shareholders. If I had free cash to deploy, it would be going here. Still expect Dr. Reddy’s acquires them in Q2 of 26 at 18 to 24. Do your dd. Deep value, strong asymmetric risk.
1 · Reply
Dubs0121
Dubs0121 Dec. 3 at 2:53 PM
$COYA we still like it here?
1 · Reply
Robby83
Robby83 Dec. 2 at 5:20 PM
$COYA added some more. Charts still looking very healthy
1 · Reply
irf944
irf944 Dec. 2 at 4:57 PM
$COYA Added. It's sitting right at support. Per Chartmill.....COYA does show a decent setup pattern. Prices have been consolidating lately. There is very little resistance above the current price. We notice that large players showed an interest for COYA in the last couple of days, which is a good sign.
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 30 at 5:40 AM
won't chase $COYA here. waiting for H% to cool like others shown
1 · Reply
mikesterz7
mikesterz7 Nov. 30 at 3:25 AM
$COYA Big news soon
1 · Reply
danws
danws Nov. 30 at 2:35 AM
$COYA trending! 🙂
1 · Reply
Jwa68
Jwa68 Nov. 30 at 2:27 AM
$COYA As can be... Expecting a leg up very soon. Deep value.
0 · Reply
ForestFoxes
ForestFoxes Nov. 30 at 1:26 AM
$GANX will trend on Stocktwits one of these days, too! Right now $COYA is trending in first position 🏁 https://gaintherapeutics.com https://coyatherapeutics.com
0 · Reply
ForestFoxes
ForestFoxes Nov. 30 at 1:22 AM
$COYA is currently trending on Stocktwits 😊 https://coyatherapeutics.com 👀
0 · Reply
Orlandotrader
Orlandotrader Nov. 29 at 2:29 PM
$COYA Need some data!!!! FTD coming soon?
0 · Reply
Jwa68
Jwa68 Nov. 27 at 10:14 AM
$COYA The importance of what Coya is doing may not be understated. It's literally a matter of life and death for some. https://www.instagram.com/reel/DM-yrVwuUIw/?igsh=MWJtajhueGpiaGl2Mg==
0 · Reply
Jwa68
Jwa68 Nov. 26 at 11:34 AM
$GANX $COYA The times are a changing...
0 · Reply
Will2ride1
Will2ride1 Nov. 26 at 2:10 AM
$COYA 7 plus
0 · Reply
DB32022
DB32022 Nov. 25 at 7:15 PM
$COYA I figured the MND symposium would be an ideal venue to present the longitudinal NFL data if it were positive. beginning to wonder if it is going to happen at all.
0 · Reply
Jwa68
Jwa68 Nov. 24 at 5:48 PM
$COYA Nice news for Coya and their 303 drug. https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies
0 · Reply
ForestFoxes
ForestFoxes Nov. 22 at 7:42 AM
$ANVS CEO, Dr. Maccecchini, tells their patients and family to buy their stock because it's the ONLY way out ☹️ Negative-Sum for Society - Erosion of Trust: Scams undermine public confidence in the legitimate biotech sector, making it harder for genuine, high-risk, but potentially life-saving ventures to attract necessary funding. - Resource Misallocation: The capital funneled into fraudulent ventures is wasted instead of being invested in legitimate, value-creating biotech research that could lead to real medical advancements such as $ACOG which is already helping patients with an FDA approved drug on the market right now and companies likes $CGTX $GANX and $COYA
3 · Reply